X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BT-600 is a drug device combination containing liquid formulation of tofacitinib (JAK inhibitor). It is being evaluated for the treatment of ulcerative colitis
Lead Product(s): Tofacitinib Citrate
Therapeutic Area: Gastroenterology Product Name: BT-600
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2024
Details:
Biora intends to use the net proceeds from this offering to support its operations, complete its ongoing BT-600 (tofacitinib) clinical trial for the treatment of moderate to severe ulcerative colitis.
Lead Product(s): Tofacitinib Citrate
Therapeutic Area: Gastroenterology Product Name: BT-600
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 03, 2024
Details:
Biora intends to use the proceeds to complete its ongoing clinical trial of BT-600, a drug-device combination consisting of the orally administered NaviCap device which delivers a unique, liquid formulation of tofacitinib to the colon for moderate to severe ulcerative colitis.
Lead Product(s): Tofacitinib Citrate
Therapeutic Area: Gastroenterology Product Name: BT-600
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 01, 2024
Details:
BT-600 (tofacitinib) is a drug-device combination program consisting of the orally administered NaviCap™ device which delivers a unique, liquid formulation of tofacitinib to the colon for the potential treatment of moderate to severe ulcerative colitis.
Lead Product(s): Tofacitinib Citrate
Therapeutic Area: Gastroenterology Product Name: BT-600
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Details:
BT-600 (tofacitinib) is a drug-device combination program consisting of the orally administered NaviCap™ device which delivers a unique, liquid formulation of tofacitinib to the colon for the potential treatment of moderate to severe ulcerative colitis.
Lead Product(s): Tofacitinib Citrate
Therapeutic Area: Gastroenterology Product Name: BT-600
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
BT-600 (tofacitinib) is a drug/device combination designed to use Biora’s NaviCap™ ingestible drug delivery device with a proprietary liquid formulation of tofacitinib. It is being evaluated for the treatment of Ulcerative Colitis.
Lead Product(s): Tofacitinib Citrate
Therapeutic Area: Gastroenterology Product Name: BT-600
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2023
Details:
BT-600 program consists of a unique, liquid formulation of tofacitinib delivered to the colon via the NaviCap device, for the treatment of ulcerative colitis. Company has submitted an updated Investigational New Drug (IND) application for the same.
Lead Product(s): Tofacitinib Citrate
Therapeutic Area: Gastroenterology Product Name: BT-600
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Details:
BT-600, a drug/device combination designed to use Biora’s NaviCap™ ingestible drug delivery device with a proprietary liquid formulation of tofacitinib, for the treatment of moderate to severe ulcerative colitis.
Lead Product(s): Tofacitinib Citrate
Therapeutic Area: Gastroenterology Product Name: BT-600
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2023
Details:
BT-600 (tofacitinib) is a drug/device combination delivering a liquid formulation of tofacitinib via the NaviCap™ platform for the treatment of ulcerative colitis.
Lead Product(s): Tofacitinib Citrate
Therapeutic Area: Gastroenterology Product Name: BT-600
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2023
Details:
The net proceeds will be used to invest in research and development of Biora's oral biotherapeutics platform, NaviCap™, a drug delivery system designed for delivery of BT-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis.
Lead Product(s): Tofacitinib Citrate
Therapeutic Area: Gastroenterology Product Name: BT-600
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $8.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 14, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
